AN2 Therapeutics, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
ANTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1800 El Camino Real, Suite D, Menlo Park, CA

Insiders trading volume in the past year

AN2 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Adjuvant Global Health Technology Fund, L.P. 10%+ Owner $45.4M -$1.97M -4.15% Jan 16, 2024
Kabeer Aziz Director $45.4M -$1.97M -4.15% Jun 19, 2024
Braden Michael Leonard 10%+ Owner $5.98M +$1.56M +35.3% Aug 14, 2024
Eric Easom Chief Executive Officer, Director $1.17M -$5.83K -0.5% Nov 18, 2024
Paul Eckburg Chief Medical Officer $983K Mar 15, 2024
Robin Shane Readnour Director $975K +$294K +43.2% Dec 6, 2024
Joseph S. Zakrzewski Director $744K -$1.88M -71.7% Nov 27, 2024
Kevin Michael Krause Chief Strategy Officer $610K -$201K -24.8% Mar 15, 2024
Lucy Day Chief Financial Officer $585K Mar 15, 2024
Sanjay Chanda Chief Development Officer $540K Mar 15, 2024
Ra Capital Management, L.P. 10%+ Owner $325K -$3.81M -92.1% Aug 9, 2024
Joshua M. Eizen Chief Operating Officer and Chief Legal Officer $131K Nov 4, 2024
Stephen David Prior Chief Strategy Officer $36.8K Nov 4, 2024
Margaret M. FitzPatrick Director Jun 19, 2024
Michael Adrian Nazak Chief Accounting Officer Feb 15, 2023
A. Martin Director Jun 19, 2024
Melvin K. Spigelman Director Jun 19, 2024
Stephanie Wong Director Jun 19, 2024
Gilbert Lynn Marks Director Jun 19, 2024

Recent Insider Transactions by Companies or Individuals for AN2 Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.